AI assistant
COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2022
Dec 28, 2022
32163_dirs_2022-12-27_9764cb14-14e0-42d7-a3d1-f3afbe8e2a66.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2022-12-22
Reporting Person: Heffernan Michael Thomas (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-22 | Common Stock | M | 237 | $16.150 | Acquired | 28260 | Direct |
| 2022-12-22 | Common Stock | S | 237 | $23.0 | Disposed | 28023 | Direct |
| 2022-12-23 | Common Stock | M | 4989 | $16.150 | Acquired | 33012 | Direct |
| 2022-12-23 | Common Stock | S | 4989 | $23.0 | Disposed | 28023 | Direct |
| 2022-12-27 | Common Stock | M | 15995 | $16.150 | Acquired | 44018 | Direct |
| 2022-12-27 | Common Stock | S | 15995 | $23.63 | Disposed | 28023 | Direct |
| 2022-12-27 | Common Stock | M | 3820 | $16.150 | Acquired | 31843 | Direct |
| 2022-12-27 | Common Stock | S | 3820 | $24.16 | Disposed | 28023 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-22 | Stock Option (Right to Purchase) | $16.150 | M | 237 | Disposed | 2026-01-20 | Common Stock (237) | Direct |
| 2022-12-23 | Stock Option (Right to Purchase) | $16.150 | M | 4989 | Disposed | 2026-01-20 | Common Stock (4989) | Direct |
| 2022-12-27 | Stock Option (Right to Purchase) | $16.150 | M | 15995 | Disposed | 2026-01-20 | Common Stock (15995) | Direct |
| 2022-12-27 | Stock Option (Right to Purchase) | $16.150 | M | 3820 | Disposed | 2026-01-20 | Common Stock (3820) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).
F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).
F4: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4).
F5: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable.